Sign In
Buy RNXT
$0.91
-0.0049 (-0.538%)
At Close: Jun 03, 2026
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
08:30am, Thursday, 28'th May 2026
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity Third FDA Orphan Drug Designation Continues to Advance Re
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
08:30am, Tuesday, 26'th May 2026
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
08:30am, Tuesday, 19'th May 2026
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies a
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
06:31pm, Thursday, 14'th May 2026
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
04:05pm, Thursday, 14'th May 2026
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ The
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:00am, Thursday, 07'th May 2026
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
08:30am, Wednesday, 29'th Apr 2026
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies
MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer
Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio wit
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
02:20pm, Wednesday, 01'st Apr 2026
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
04:05pm, Monday, 30'th Mar 2026
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipa
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
08:30am, Thursday, 26'th Mar 2026
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for D
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
08:30am, Monday, 23'rd Mar 2026
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones Company has the funding, business plan, leadership and infras
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies
